European journal of cancer (Oxford, England : 1990) · 2026
Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors.
СтатьяКлиническое исследование I фазыМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Papadopoulos Kyriakos P, Sharma Manish R, Dummer Reinhard, Colombo Ilaria, Ramelyte Egle, Seamon Leigh, Rasco Drew W, Rodriguez-Freixinos Victor, Dozio Vito, Tat Tri, Luong Noemie, Mathon Caroline, Fuchs Jeannette, Massiere Frederic, Hurynovich Aliaksandr, Omar Mokhtar, Micallef Sandrine, Bellon Anne, Rodrigo Imedio Esteban, Stathis Anastasios
Аннотация
PURPOSE: The DNA damage-activated G2/M and S phase cell cycle checkpoint regulator WEE1 kinase is an attractive therapeutic target for solid tumors. We report the results of the dose escalation part of a phase 1 trial assessing the WEE1 inhibitor Debio 0123.
PATIENTS AND METHODS: The study enrolled patients with relapsed/refractory advanced solid tumors. Debio 0123 was given orally, once daily. Safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics were assessed.
RESULTS: Twenty-seven patients were treated with Debio 0123 at doses ranging from 30 to 350 mg. Any grade treatment-related adverse events (TRAEs) were experienced by 92.6% of patients. The most frequent events were increased blood creatinine and QT interval corrected using Fridericia's formula (QTcF) prolongation (37% each). Grade 3 TRAEs were experienced by 33.3% of patients; QTcF prolongation (11%, only observed at 350 mg) and fatigue (7%) were the most common. The maximum tolerated dose and recommended phase 2 dose of Debio 0123 was 260 mg once daily. Proportional pharmacokinetics were seen up to 350 mg, the highest dose level tested. In paired skin biopsies, decreased phosphorylation of the WEE1 target CDC2 was consistently observed at doses ≥200 mg. Exploratory analysis of efficacy showed eight patients (32%) with stable disease as best response, including 5 tumor regressions (up to 20%).
CONCLUSIONS: Debio 0123 demonstrated a manageable toxicity profile, exhibited linear pharmacokinetics and showed target engagement at doses ≥200 mg. Given the response observed in a subset of this heavily pre-treated population, results support further investigation of Debio 0123 in selected indications.
PATIENTS AND METHODS: The study enrolled patients with relapsed/refractory advanced solid tumors. Debio 0123 was given orally, once daily. Safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics were assessed.
RESULTS: Twenty-seven patients were treated with Debio 0123 at doses ranging from 30 to 350 mg. Any grade treatment-related adverse events (TRAEs) were experienced by 92.6% of patients. The most frequent events were increased blood creatinine and QT interval corrected using Fridericia's formula (QTcF) prolongation (37% each). Grade 3 TRAEs were experienced by 33.3% of patients; QTcF prolongation (11%, only observed at 350 mg) and fatigue (7%) were the most common. The maximum tolerated dose and recommended phase 2 dose of Debio 0123 was 260 mg once daily. Proportional pharmacokinetics were seen up to 350 mg, the highest dose level tested. In paired skin biopsies, decreased phosphorylation of the WEE1 target CDC2 was consistently observed at doses ≥200 mg. Exploratory analysis of efficacy showed eight patients (32%) with stable disease as best response, including 5 tumor regressions (up to 20%).
CONCLUSIONS: Debio 0123 demonstrated a manageable toxicity profile, exhibited linear pharmacokinetics and showed target engagement at doses ≥200 mg. Given the response observed in a subset of this heavily pre-treated population, results support further investigation of Debio 0123 in selected indications.